Head and Neck Cancer Immunotherapy: SITC 2024 Guideline Summary
This guideline summary updates recommendations for the use of PD‑1 inhibitors in squamous cell carcinoma of the head and neck, offering detailed guidance on first‑line versus second‑line therapy, biomarker testing, HPV status, treatment response, and adverse event management.
The Society for Immunotherapy of Cancer (SITC) 2024 consensus statement revises its 2019 guidance on immunotherapy for recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC). It details indications for PD‑1 inhibitor monotherapy and combination with chemotherapy, biomarker requirements (PD‑L1 CPS ≥1), HPV status considerations, and strategies for treatment sequencing, response evaluation, and immune‑related adverse event management.
PD‑1 inhibitors are a cornerstone of first‑line therapy for R/M HNSCC, improving overall response rates and survival while providing a treatment framework that balances efficacy and safety.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability